{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:21:30Z","timestamp":1792045290851,"version":"4.4.0"},"reference-count":46,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guselkumab is an interleukin (IL)\u201023 inhibitor with demonstrated efficacy in patients with psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Evaluate the impact of early disease intervention on clinical responses following 28\u2009weeks of guselkumab treatment in patients with moderate\u2010to\u2010severe plaque psoriasis. Correlate clinical response and disease duration data with serum biomarker data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>GUIDE is a phase IIIb randomized, double\u2010blind, parallel\u2010group, multicentre study of adults with moderate\u2010to\u2010severe plaque psoriasis. In study part 1, patients with a short disease duration (SDD [\u22642\u2009years]) or a long disease duration (LDD [&gt;2\u2009years]) received guselkumab 100\u2009mg at Week (W) 0, 4, 12, and 20. Those achieving complete skin clearance at W20 and W28 were defined as a super responder (SRe). A multivariable logistic regression analysed the association between baseline factors and the likelihood of becoming an SRe. The relationship between clinical response, disease duration and serum biomarker data was assessed at W0 and 4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 880 patients were enrolled (SDD\/LDD\u2009=\u200940.6%\/59.4% of patients). More SDD than LDD patients achieved absolute Psoriasis Area and Severity Index (PASI)\u2009=\u20090 at W28 (51.8% vs. 39.4%) and were SRes (43.7% vs. 28.1% [overall 34.4%]). SDD patients also achieved PASI\u2009=\u20090 quicker than LDD patients (median 141 vs. 200\u2009days). Disease duration and prior biologic use had the greatest impact on becoming an SRe, with no strong association among these independent variables. At baseline, there were no significant differences in the serum biomarker levels of IL\u201017A, IL\u201017F, IL\u201022 and \u03b2\u2010defensin 2 between SDD and LDD patients, or between SRe and non\u2010SRe patients. Guselkumab rapidly decreased these markers of systemic inflammation across all patient groups analysed at W4. Guselkumab was well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Guselkumab efficacy was consistent across subpopulations, on the skin and systemically. The proportion of SRes was higher in SDD than LDD patients, indicating early treatment intervention may improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.19236","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T14:29:35Z","timestamp":1685629775000},"page":"2016-2027","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): Week 28 results from the ongoing phase\n                    <scp>IIIb<\/scp>\n                    randomized, double\u2010blind, parallel\u2010group,\n                    <scp>GUIDE<\/scp>\n                    study"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-7799","authenticated-orcid":false,"given":"K.","family":"Sch\u00e4kel","sequence":"first","affiliation":[{"name":"Department of Dermatology, and Interdisciplinary Center for Inflammatory Diseases Heidelberg University Hospital  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-4332","authenticated-orcid":false,"given":"K.","family":"Reich","sequence":"additional","affiliation":[{"name":"Translational Research in Inflammatory Skin Diseases University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Asadullah","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin  Berlin Germany"},{"name":"Prof. Dr. med. Asadullah, Dermatological Practice  Potsdam Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1502","authenticated-orcid":false,"given":"A.","family":"Pinter","sequence":"additional","affiliation":[{"name":"University Hospital Frankfurt am Main  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2995-7928","authenticated-orcid":false,"given":"D.","family":"Jullien","sequence":"additional","affiliation":[{"name":"Department of Dermatology Edouard Herriot Hospital, Hospices Civils de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Weisenseel","sequence":"additional","affiliation":[{"name":"Dermatologikum Hamburg  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paul","sequence":"additional","affiliation":[{"name":"Toulouse University  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gomez","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wegner","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8631-518X","authenticated-orcid":false,"given":"Y.","family":"Personke","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Kreimendahl","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9534-6199","authenticated-orcid":false,"given":"Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Janssen R&amp;D, LLC  San Diego USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Angsana","sequence":"additional","affiliation":[{"name":"Janssen R&amp;D, LLC  San Diego USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. W. L.","family":"Leung","sequence":"additional","affiliation":[{"name":"Janssen R&amp;D, LLC  San Diego USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Eyerich","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical Center University of Freiburg  Freiburg im Breisgau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800013"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042915-103905"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-015-1613-8"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12118"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14684"},{"key":"e_1_2_10_10_1","first-page":"48","article-title":"German psoriasis registry PsoBest: objectives, methodology and baseline data","volume":"12","author":"Augustin M","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16568"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.01.005"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3010641"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93396"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08902.x"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0094-4"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.07.007"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.018"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13561"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.05.016"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000475809"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.06.038"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200535503"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041275"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-009-0457-0"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.139"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53240-z"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.200"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2015.11.007"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.05.016"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.01.025"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092254"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61000-4"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2014.880396"},{"key":"e_1_2_10_35_1","unstructured":"LiuD BraniganP ChenY BanaszewskaM McGovernP FakharzadehS et al.Identification of clinical and biomarker parameters associated with long\u2010term maintenance of PASI 90 response following guselkumab treatment\u2010withdrawal in psoriasis.27th EADV Congress. Paris France. 2018; Abstract P1894."},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18474"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049822"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302313"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2019.06.002"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17748"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.03.019"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3254"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/24755303221127338"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18846"},{"key":"e_1_2_10_47_1","doi-asserted-by":"crossref","unstructured":"IversenL ConradC K\u00e4rnerJ K\u00e4rnerJ CostanzoA CardnerM et al.Secukinumab normalizes skin transcriptomes to a non\u2010lesional state in new\u2010onset psoriasis patients more rapidly than in chronic patients.51st ESDR meeting Amsterdam The Netherlands2022; P365.","DOI":"10.26226\/m.62fa009ddcd2c8001911ead5"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T09:15:09Z","timestamp":1711012509000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/jdv.19236"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19236","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"2022-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}